These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 20153976)

  • 1. HIV-1 elite controllers: beware of super-infections.
    Clerc O; Colombo S; Yerly S; Telenti A; Cavassini M
    J Clin Virol; 2010 Apr; 47(4):376-8. PubMed ID: 20153976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recovery of viremic control after superinfection with pathogenic HIV type 1 in a long-term elite controller of HIV type 1 infection.
    Rachinger A; Navis M; van Assen S; Groeneveld PH; Schuitemaker H
    Clin Infect Dis; 2008 Dec; 47(11):e86-9. PubMed ID: 18947331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune activation and antibody responses in non-progressing elite controller individuals infected with HIV-1.
    Bello G; Velasco-de-Castro CA; Bongertz V; Rodrigues CA; Giacoia-Gripp CB; Pilotto JH; Grinsztejn B; Veloso VG; Morgado MG
    J Med Virol; 2009 Oct; 81(10):1681-90. PubMed ID: 19697415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How do HIV elite controllers do what they do?
    Saag M; Deeks SG
    Clin Infect Dis; 2010 Jul; 51(2):239-41. PubMed ID: 20550453
    [No Abstract]   [Full Text] [Related]  

  • 5. Elite controllers as a model of functional cure.
    Autran B; Descours B; Avettand-Fenoel V; Rouzioux C
    Curr Opin HIV AIDS; 2011 May; 6(3):181-7. PubMed ID: 21460722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coinfection and superinfection in patients with long-term, nonprogressive HIV-1 disease.
    Casado C; Pernas M; Alvaro T; Sandonis V; García S; Rodríguez C; del Romero J; Grau E; Ruiz L; Lopez-Galindez C
    J Infect Dis; 2007 Sep; 196(6):895-9. PubMed ID: 17703421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The study of elite controllers: a pure academic exercise or a potential pathway to an HIV-1 vaccine?
    Blankson JN
    Curr Opin HIV AIDS; 2011 May; 6(3):147-50. PubMed ID: 21399493
    [No Abstract]   [Full Text] [Related]  

  • 8. Progression of HIV to AIDS: a protective role for HLA-B27?
    den Uyl D; van der Horst-Bruinsma IE; van Agtmael M
    AIDS Rev; 2004; 6(2):89-96. PubMed ID: 15332431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 reservoirs in elite controllers: clues for developing a functional cure?
    May ME; Kwaa AK; Blankson JN
    Future Microbiol; 2017 Sep; 12():1019-1022. PubMed ID: 28836451
    [No Abstract]   [Full Text] [Related]  

  • 10. Virologic and host characteristics of human immunodeficiency virus type 1-infected pediatric long term survivors.
    Alexander L; Cuchura L; Simpson BJ; Andiman WA
    Pediatr Infect Dis J; 2006 Feb; 25(2):135-41. PubMed ID: 16462290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiological, immunological and virological characteristics, and disease progression of HIV-1/HCV-co-infected patients from a southern Brazilian population.
    Reiche EM; Bonametti AM; Morimoto HK; Morimoto AA; Wiechemann SL; Matsuo T; Vissoci Reiche F; Vogler IH
    Int J Mol Med; 2008 Mar; 21(3):387-95. PubMed ID: 18288387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms involved in non-progressive HIV disease.
    Mikhail M; Wang B; Saksena NK
    AIDS Rev; 2003; 5(4):230-44. PubMed ID: 15012002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elucidating the elite: mechanisms of control in HIV-1 infection.
    O'Connell KA; Bailey JR; Blankson JN
    Trends Pharmacol Sci; 2009 Dec; 30(12):631-7. PubMed ID: 19837464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of GBV-C infection in HIV-1 infected patients.
    Canducci F; Uberti Foppa C; Boeri E; Racca S; Gallotta G; Grasso MA; Calori G; Lazzarin A; Clementi M
    J Biol Regul Homeost Agents; 2003; 17(2):191-4. PubMed ID: 14518722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 and AIDS: what are protective immune responses?
    Beattie T; Rowland-Jones S; Kaul R
    J HIV Ther; 2002 May; 7(2):35-9. PubMed ID: 12553686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Slow progression of HIV-1 infection in a cohort of antiretroviral naïve hotel workers in Dar es Salaam, Tanzania as defined by their CD4 cell slopes.
    Bakari M; Urassa W; Mhalu F; Biberfeld G; Pallangyo K; Sandström E
    Scand J Infect Dis; 2008; 40(5):407-13. PubMed ID: 17943637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination antiretroviral therapy failure and HIV super-infection.
    Bezemer D; van Sighem A; de Wolf F; Cornelissen M; van der Kuyl AC; Jurriaans S; van der Hoek L; Prins M; Coutinho RA; Lukashov VV
    AIDS; 2008 Jan; 22(2):309-11. PubMed ID: 18097235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic correlates of protection against HIV infection: the ally within.
    Piacentini L; Biasin M; Fenizia C; Clerici M
    J Intern Med; 2009 Jan; 265(1):110-24. PubMed ID: 19093964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology and clinical characteristics of elite controllers.
    Okulicz JF; Lambotte O
    Curr Opin HIV AIDS; 2011 May; 6(3):163-8. PubMed ID: 21502920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effector HIV-specific cytotoxic T-lymphocyte activity in long-term nonprogressors: associations with viral replication and progression.
    Keoshkerian E; Ashton LJ; Smith DG; Ziegler JB; Kaldor JM; Cooper DA; Stewart GJ; Ffrench RA
    J Med Virol; 2003 Dec; 71(4):483-91. PubMed ID: 14556259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.